Trial · NCT02964273
Results by group603
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 603
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose) | Phase A: Tolvaptan | Baseline | 635 | Standard Deviation 252 | milliosmoles per kilogram (mOsm/kg) |
| Phase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose) | Phase A: Placebo | Baseline | 646 | Standard Deviation 250 | milliosmoles per kilogram (mOsm/kg) |
| Phase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose) | Phase A: Tolvaptan | Change From Baseline at Week 1, Phase A | -386 | Standard Deviation 284 | milliosmoles per kilogram (mOsm/kg) |
| Phase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose) | Phase A: Placebo | Change From Baseline at Week 1, Phase A | -93 | Standard Deviation 332 | milliosmoles per kilogram (mOsm/kg) |
| Phase A: Change From Baseline in Specific Gravity (Pre-morning Dose) | Phase A: Tolvaptan | Baseline | 1.017 | Standard Deviation 0.006 | ratio |
| Phase A: Change From Baseline in Specific Gravity (Pre-morning Dose) | Phase A: Placebo | Baseline | 1.017 | Standard Deviation 0.006 | ratio |
| Phase A: Change From Baseline in Specific Gravity (Pre-morning Dose) | Phase A: Tolvaptan | Change From Baseline at Week 1, Phase A | -0.009 | Standard Deviation 0.007 | ratio |
| Phase A: Change From Baseline in Specific Gravity (Pre-morning Dose) | Phase A: Placebo | Change From Baseline at Week 1, Phase A | -0.002 | Standard Deviation 0.008 | ratio |
| Phase A: Percent Change From Phase A Baseline in Height-Adjusted Total Kidney Volume (htTKV) as Measured by Magnetic Resonance Imaging (MRI) | Phase A: Tolvaptan | 2.28 | Standard Deviation 8.75 | percent change | |
| Phase A: Percent Change From Phase A Baseline in Height-Adjusted Total Kidney Volume (htTKV) as Measured by Magnetic Resonance Imaging (MRI) | Phase A: Placebo | 6.11 | Standard Deviation 7.48 | percent change | |
| Phase A and B: Mean 24-hour Fluid Balance Prior to Week 1 | Phase A: Tolvaptan | 31 | Standard Deviation 1978 | milliliter | |
| Phase A and B: Mean 24-hour Fluid Balance Prior to Week 1 | Phase A: Placebo | 241 | Standard Deviation 867 | milliliter | |
| Phase A and B: Mean 24-hour Fluid Balance Prior to Week 1 | Phase B: Prior Tolvaptan | 138 | Standard Deviation 1382 | milliliter | |
| Phase A and B: Mean 24-hour Fluid Balance Prior to Week 1 | Phase B: Prior Placebo | 207 | Standard Deviation 1355 | milliliter | |
| Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A | Phase A: Tolvaptan | Baseline | 93.9 | Standard Deviation 18.7 | mL/min/1.73 m^2 |
| Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A | Phase A: Placebo | Baseline | 102.1 | Standard Deviation 15.4 | mL/min/1.73 m^2 |
| Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A | Phase A: Tolvaptan | Change From Baseline at Month 1, Phase A | 2.8 | Standard Deviation 10.7 | mL/min/1.73 m^2 |
| Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A | Phase A: Placebo | Change From Baseline at Month 1, Phase A | -1.9 | Standard Deviation 8.8 | mL/min/1.73 m^2 |
| Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A | Phase A: Tolvaptan | Change From Baseline at Month 6, Phase A | 4.6 | Standard Deviation 10.1 | mL/min/1.73 m^2 |
| Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A | Phase A: Placebo | Change From Baseline at Month 6, Phase A | -2.5 | Standard Deviation 11.1 | mL/min/1.73 m^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02964273/results